Compounded Ketamine Tablet: What You Need to Know

Compounded ketamine tablet what you need to know starts with one fact: most ketamine tablets, troches, and capsules used for psychiatric and pain treatment are not made by a major pharmaceutical company. They are compounded, meaning a specialty pharmacy prepares each batch individually based on a licensed prescriber's order. No FDA-approved oral ketamine tablet exists for these off-label psychiatric uses, so compounding pharmacies fill a gap that commercial manufacturing does not cover. Compounding has been part of pharmacy practice for centuries, long before mass drug production began, and for ketamine it lets prescribers offer doses and forms, such as sublingual troches or oral capsules, that no drugmaker currently sells for outpatient use.

Compounding is the process of preparing a customized medication for a specific patient based on a licensed prescriber's order. It predates mass drug manufacturing: before large-scale production began, pharmacists prepared every medication this way, one patient at a time.

Today, compounding fills a specific gap. It gives prescribers access to doses, forms, or combinations that no commercial manufacturer sells. For ketamine, compounding is necessary because no FDA-approved oral ketamine tablet exists for psychiatric indications, patients often need doses that differ from the concentrations sold for injectable use, and oral forms such as troches, tablets, and capsules are not produced by major pharmaceutical companies for outpatient use. Our ketamine tablet overview covers why an FDA-approved oral product does not yet exist.

The FDA regulates compounding pharmacies under two sections of the Federal Food, Drug, and Cosmetic Act, described in the FDA's human drug compounding guidance.

503A pharmacies prepare medication for an identified patient based on a valid prescription. They are regulated mainly by state pharmacy boards and follow United States Pharmacopeia (USP) standards, an independent standards-setting body that publishes benchmarks for sterile and non-sterile compounding. A 503A pharmacy cannot produce large batches in advance for general sale. Most pharmacies that prepare ketamine troches, tablets, and capsules operate under 503A.

503B outsourcing facilities operate under direct FDA oversight, closer to how a pharmaceutical manufacturer is regulated. They can produce larger batches without a patient-specific prescription and must register with the FDA. Some 503B facilities produce ketamine formulations, particularly for clinical or hospital use.

Active pharmaceutical ingredient (API). The ketamine itself, specifically ketamine hydrochloride, comes from DEA-registered API suppliers. Reputable pharmacies use pharmaceutical-grade ketamine HCl with certificates of analysis from qualified suppliers.

Base or vehicle. The base determines the physical form and affects absorption. Troches often use a base of polyethylene glycol (PEG) 1000 or cocoa butter that dissolves slowly in the mouth; see our guide to what ketamine troches are. Tablets use standard excipients such as microcrystalline cellulose and magnesium stearate. Capsules combine ketamine powder with an inert filler in a gelatin or HPMC shell. The base a pharmacy chooses can affect how much of the dose reaches the bloodstream.

Flavorings and preservatives. Ketamine has a bitter, unpleasant taste, so compounders add flavoring, such as mint, grape, or bubblegum, to troches and oral solutions, and may coat tablets to mask the taste. Oral liquids also require preservatives to prevent microbial growth, which affects shelf life and tolerability.

Getting a compounded ketamine tablet prescription filled generally involves four steps. First, a licensed prescriber, such as a physician, psychiatrist, or nurse practitioner, evaluates you and determines whether ketamine is appropriate. Second, that prescriber writes a valid prescription specifying the drug, dose, form, quantity, and directions. Third, you or your prescriber select a compounding pharmacy, either one your prescriber already works with or one you choose yourself. Fourth, the pharmacy fills the prescription under controlled substance rules, since ketamine is a Schedule III controlled substance according to the DEA's drug scheduling system, meaning it has an accepted medical use alongside a recognized potential for abuse and dependence.

Compounded ketamine tablets are generally not covered by health insurance, since this is an off-label use of a compounded preparation rather than an FDA-approved drug. Out-of-pocket costs vary by pharmacy, dose, and form: troches typically run about $12 to $30 per unit, tablets and capsules about $8 to $20 per unit, and monthly costs for daily maintenance dosing can range from roughly $200 to $600 or more depending on dose and frequency. Some patients use FSA or HSA funds for these costs, and receipts from a licensed pharmacy generally qualify. Our article on the insurance coverage gap for oral ketamine covers this in more detail.